ROLE OF GENERICS IN TREATMENT OF HEPATITIS C INFECTION
Abstract
With the discovery of newer and newer DAAs, the cure of Hepatitis C seems to be a reality. But their high price and availability is a big hindrance. Sofosbuvir launched byGileadcosts about $ 84000 per 12-week course. Since its launch there is a huge debate regarding the complex pricing mechanism of DAAs. The pricing involves negotiation of patent holder with health insurance companies through their Pharmacy Benefit Managers (PBMs). Several rebates are also involved in this pricing mechanism amongst which only few are declared ones. Different countries are adapting different strategies to overcome this pricing issue. The branded companies have also issued licenses to companies to form generic version of the drugs and to market them to selected middle and low income countries. Few countries that are not in the list have rejected the patent and started producing their own generics. It is due to these generics that the price of DAAs had undergone a significant reduction but their manufacturing and efficacy needs regular scrutiny.Keywords: Generics, Pricing; Direct Acting Antivirals (DAAs); Hepatitis C VirusReferences
ISGlobal Barcelona institute of global health. Hepatitis C: The New Battleground for Access to Essential Medicines. [Internet]. [cited 2016 Oct 6]. Available from: http://www.isglobal.org/documents/10179/5353835/Informe+25+Hepatitis+C+eng/4fa21b0d-9199-4e99-9f0b-c056126a77eb
Overview of cost, reimbursement, and cost-effectiveness considerations for hepatitis c treatment regimens. Recommendations for Testing, Managing, and Treating Hepatitis C [Internet]. [cited 2016 Oct 6]. Available from: http://www.hcvguidelines.org/full-report/overview-cost-reimbursement-and-cost-effectiveness-considerations-hepatitis-c-treatment
Rosenthal ES, Graham CS. Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Infect Agent Cancer 2016;11:24.
Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Minimum costs for producing Hepatitis C Direct Acting Antivirals, for use in large-scale treatment access programs in developing countries. Clin Infect Dis 2014;58(7):928–36.
Drugs for neglected diseases initiative. An alternative research and development strategy to deliver affordable treatments for hepatitis C patients. [Internet]. [cited 2016 Oct 6]. Available from: http:// http://www.dndi.org/wp-content/uploads/2016/04/AlternativeRDStrategyHepC.pdf
Hill A, Simmons B, Gotham D, Fortunak J. Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C. J Virus Erad 2016;2(1):28–31.
Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 2015;16l2(9):619–29.
Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 2015;61(6):1860–9.
Gilead Sciences Inc. Chronic hepatitis C treatment expansion: generic manufacturing for developing countries. [Internet]. 2015 [cited 2016 Oct 6]. Available from: http://www.gilead.com/~/media/files/pdfs/other/hcv%20generic%20agreement%20fast%20facts%20101615.pdf?la=en
Gilead Sciences Inc. original HCV license agreement. 2014 [Internet] [cited 2016 Oct 6]. Available from: https://www.gilead.com/~/media/files/pdfs/other/2014_original_hcv_licensing_agreement.pdf?la=en
China rejects Gilead patent on hepatitis C drug sofosbuvir. Médecins Sans Frontières (MSF/Doctors Without Borders) [Internet]. [cited 2016 Oct 6]. Available from: http://msf-seasia.org/news/16406
Gokhale K, Kitamura M. $10 Copy of Gilead Blockbuster Sovaldi Appears in Bangladesh - Bloomberg [Internet]. [cited 2016 Oct 6]. Available from: http://www.bloomberg.com/news/articles/2015-03-08/-10-copy-of-gilead-s-blockbuster-sovaldi-appears-in-bangladesh
Bristol-Myers Squibb: HCV Developing World Strategy [Internet]. [cited 2016 Oct 4]. Available from: http://www.bms.com/responsibility/access-to-medicines/Pages/HCV-developing-world-strategy.aspx
Gower E, Estes C, Blach S, Shearer KR, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(1 Suppl):S45–57.
Akhter TS, Umar M, Umar S, Nisar G, Shehzad A, Naseer A, et al. Su1461 Trends of Sofosbuvir treatment for Chronic Hepatitis C infection in Genotype 3 patients—an experience from Center for Liver and Digestive Diseases Pakistan. Gastroenterology 2016;150(4): S1106.
Akhter TS, Umer M, Bushra HT, Shehzad A, Nisar G, Bilal M, et al. Response to Sofosbuvir treatment for Chronic Hepatitis C infection in Genotype 3 patients—an experience from Center for Liver and Digestive Diseases Pakistan. Gastro. Forthcoming 2016.
Farooqi JI, Humayun M, Chaudhry A, Sadik M, Uddin Z, Alam A, et al. Multi-center experience using Sofosbuvir & Ribavirin with and without pegylated interferon to treat hepatitis C patients with and without liver cirrhosis (RESiP Study: Real-life Experience with Sofosbuvir in Pakistan). In WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2016. p.962A.
Reddy KR, Lim JK, Kuo A, Di Bisceglie A, Vargas H, Galati J, et al. All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: report from HCV-TARGET. J Hepatol. 2015;62(Suppl 2):S193.
Samuel D, Manns M, Forns X, Flamm SL, Reddy KR, Denning J, et al. Ledipasvir/sofosbuvir with ribavirin is safe in [600 decompensated and post liver transplantation patients with HCV infection: an integrated safety analysis of the solar 1 and solar 2 trials. J Hepatol 2015;62:S620–2.
Waked I, Doss W, El-Sayed MH, Razavi H, Shiha G, Yosry A, et al. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol 2014;15(2):45–52.
Doss W, Esmat G, El Serafy M, El Sayed M, Hassany M, Yousry A, et al. Interim analysis for sofosbuvir national treatment program in Egypt. In Wiley Online Library; 2015. p.94–94.
Juniastuti K, Wibowo BP, Wibawa ID, Utsumi T, Mustika S, Amin M, et al. Interleukin-28B polymorphisms and response of chronic hepatitis C patients from Indonesia to Pegylated Interferon/ Ribavirin treatment. J Clin Microbiol 2014;52(6):2193–5.
amfAR: How Activists Are Driving Down the Cost of Hepatitis C Treatment in Asia: The Foundation for AIDS Research: HIV / AIDS Research [Internet]. [cited 2016 Sep 30]. Available from: http://www.amfar.org/activists-driving-down-cost-hepatitis-c-treatment/
WHO. Global Hepatitis Programme. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. [Internet]. 2016 [cited 2016 Aug 30]. Available from: http://apps.who.int/iris/bitstream/10665/205035/1/9789241549615_eng.pdf
Andrieux-Meyer I, Cohn J, de Araújo ES, Hamid SS. Disparity in market prices for hepatitis C virus direct-acting drugs. Lancet Glob Health 2015;3(11):e676–7.
Freeman J, Sallie R, Kennedy A, Hieu PT, Jeffreys G, Hill AM. High sustained virological response rates using generic Direct Acting Antiviral treatment for Hepatitis C, imported into Australia. J Hepatol2016;2(64):S209.
infohep. How generic direct-acting antivirals are changing the landscape for hepatitis C treatment. [Internet]. [cited 2016 Aug 30]. Available from: http://www.infohep.org/How-generic-direct-acting-antivirals-are-changing-the-landscape-for-hepatitis-C-treatment/page/3051430/
Crespo-Casal M. Treatment guidelines for Hepatitis C in Spain. Rev Esp Sanid Penit 2015;17(2):37–47.
Study by Global Hospitals Shows Generic Hepatitis C Drugs Effective in Treating the Disease /PR Newswire India/ [Internet]. [cited 2016 Oct 8]. Available from: http://www.prnewswire.co.in/news-releases/study-by-global-hospitals-shows-generic-hepatitis-c-drugs-effective-in-treating-the-disease-588741281.html
Published
Issue
Section
License
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
